PepGen Inc Stock Price, News & Analysis

PepGen Inc. (Nasdaq: PEPG) is set to report its fourth quarter and full year 2022 financial results on March 23, 2023. The clinical-stage biotechnology company focuses on advancing oligonucleotide therapies to treat severe neuromuscular and neurological diseases. PepGen's management will also host a conference call and audio webcast at 4:30 PM ET to discuss these results. The company employs an Enhanced Delivery Oligonucleotide (EDO) platform, leveraging cell-penetrating peptides to enhance therapeutic uptake and effectiveness. A replay of the event will be archived for one year.

PepGen Inc. (Nasdaq: PEPG) announced its participation in the Muscular Dystrophy Association (MDA) Annual Clinical and Scientific Conference from March 19-22, 2023, in Dallas, Texas. The company plans to present data on PGN EDO51 for Duchenne Muscular Dystrophy and PGN-EDODM1 for Myotonic Dystrophy Type 1, with presentations scheduled for March 22. Notably, PepGen will release a press statement after its presentations and provide access to the poster and data presentations on its Investor Relations website. The company's Enhanced Delivery Oligonucleotide platform aims to advance treatments for severe neuromuscular and neurological diseases.

PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company, announced that its President and CEO, James McArthur, Ph.D., will present at the SVB Securities’ Global Biopharma Virtual Conference on February 16, 2023, at 10:40 A.M. EST. The presentation aims to highlight PepGen's next-generation oligonucleotide therapies designed to transform treatment for severe neuromuscular and neurological diseases.

The event will be available for live streaming, and a replay will be accessible on PepGen's website for 90 days afterward. The company focuses on enhancing the delivery of oligonucleotide therapeutics through its Enhanced Delivery Oligonucleotide (EDO) platform.

PepGen Inc. has announced positive preclinical results for PGN-EDODM1, a treatment for myotonic dystrophy type 1 (DM1). The product candidate, which uses Enhanced Delivery Oligonucleotide technology, has demonstrated a well-tolerated safety profile in studies with no off-target effects. Notably, it does not degrade DMPK transcripts, an important safety consideration. PepGen plans to initiate a single ascending dose clinical trial in DM1 patients in the first half of 2023. This marks a significant step forward as there are currently no approved therapies for DM1.

PepGen Inc. (NASDAQ: PEPG) announced promising exon skipping results from its product candidates PGN-EDO53, PGN-EDO45, and PGN-EDO44 for Duchenne muscular dystrophy (DMD). In non-human primates (NHPs), PGN-EDO53 achieved exon skipping levels of 36.4% after one dose and 57.2% after three doses, significantly outperforming the comparator PPMO molecule. Additionally, PGN-EDO45 and PGN-EDO44 demonstrated high exon skipping in human myoblasts, indicating potential for treating approximately 50% of DMD patients amenable to exon skipping. The results affirm PepGen's Enhanced Delivery Oligonucleotide platform's transformative potential.

PepGen Inc. (Nasdaq: PEPG) reported its Q3 2022 results, highlighting successful Phase 1 trial data for PGN-EDO51, indicating high levels of oligonucleotide delivery and exon skipping in DMD patients. With cash reserves of $195.8 million, R&D expenses rose to $16 million, which is significantly higher than last year's $5.7 million. The net loss increased to $18.6 million from $8.1 million year-over-year. Upcoming milestones include initiating Phase 2a trials for PGN-EDO51 and Phase 1/2 trials for PGN-EDODM1 in the first half of 2023.

PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company, announced that its President and CEO, James McArthur, will present at Stifel’s 2022 Annual Healthcare Conference on November 15, 2022, at 9:45 A.M. ET in New York. The presentation aims to highlight PepGen's innovative oligonucleotide therapies for severe neuromuscular and neurological diseases. A live webcast will be accessible on PepGen’s website, with a replay available for 90 days. PepGen's Enhanced Delivery Oligonucleotide (EDO) platform focuses on improving therapeutic efficacy through advanced cell-penetrating peptides.

PepGen Inc. (Nasdaq: PEPG) presented new data at the 27th International Hybrid Annual Congress of the World Muscle Society regarding its Duchenne muscular dystrophy (DMD) program, focusing on its lead candidate, PGN-EDO51. The data showed significant exon skipping and dystrophin restoration in both non-human primates and mouse models. Highlights include up to 93.1% exon skipping in murine models with PGN-EDO23 and 78% exon skipping in non-human primates with PGN-EDO51. The technology aims to improve oligonucleotide delivery for treating severe neuromuscular diseases.

PepGen Inc. (Nasdaq: PEPG) announced positive results from its Phase 1 trial of PGN-EDO51 for Duchenne muscular dystrophy (DMD). The clinical study demonstrated high levels of oligonucleotide delivery and exon skipping, exceeding previous therapies. The trial's primary endpoint was met, showing PGN-EDO51 was well-tolerated with mild adverse events. PepGen plans to initiate a Phase 2a multiple ascending dose trial in DMD patients in the first half of 2023, bolstered by findings suggesting potential accumulation of therapeutic proteins with repeated dosing.